Telix Pharmaceuticals Ltd
No SEC Form 4 filings for $TLX in the last 30 days.
ASX 200 ended slightly lower on the day, down 0.09% to 9,263.60, but rose 3.2% for the week. Materials gained 1.32% as gold prices neared $4,300/oz. Gold and lithium stocks led, including Genesis Minerals (GMD), Capricorn Metals (CMM), Vault Minerals (VAU) and Liontown (LTR). ResMed (RMD) and 4DMedical (4DX) fell.
A weekly ASX short-selling recap (data lagged 4 days) lists the 10 most shorted stocks and the biggest changes in short interest. Healius entered the top ten, replacing Treasury Wine. Lotus Resources saw a 57.5% one-day short-interest dip after a $60m raise at 22c. Web Travel Group’s short interest fell ahead of a guidance beat and up to $90m buyback; shares rose 17.1%.
Simply Wall St reports Telix Pharmaceuticals (ASX:TLX) said in July 2026 it saw positive Phase 1 ProstACT SELECT data for TLX591-Tx, dosed the first patient in Phase 3 LUTEON for TLX250-Tx, and entered a collaboration with Regeneron. Telix raised FY26 revenue guidance to above US$1B and reported Q2 revenue of US$247M.
Over the past 7 days, alphai's AI scored 3 news stories mentioning TLX (Telix Pharmaceuticals Ltd). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent TLX coverage spans market movers, financial news and earnings.
The move is presented as part of the day’s top performers, but the article provides no new TLX catalyst.
Shorts appear to be easing over the month, which can reduce downside hedging pressure.
Higher FY2026 revenue guidance and new clinical/pipeline milestones can re-rate near-term commercial execution while keeping trial and regulatory overhangs in focus.
Near-term catalyst is the Aug 20 H1 financial release plus ongoing clinical validation for TLX591-Tx from ProstACT SELECT.
The article suggests TLX’s decline is valuation-driven rather than earnings collapse, given sharply rising forecast EPS.
alphai scores every news story that mentions TLX with an AI model for sentiment and relevance, and aggregates insider trades from Telix Pharmaceuticals Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
ASX 200 ended slightly lower on the day, down 0.09% to 9,263.60, but rose 3.2% for the week. Materials gained 1.32% as gold prices neared $4,300/oz. Gold and lithium stocks led, including Genesis Minerals (GMD), Capricorn Metals (CMM), Vault Minerals (VAU) and Liontown (LTR). ResMed (RMD) and 4DMedical (4DX) fell.
4 min readA weekly ASX short-selling recap (data lagged 4 days) lists the 10 most shorted stocks and the biggest changes in short interest. Healius entered the top ten, replacing Treasury Wine. Lotus Resources saw a 57.5% one-day short-interest dip after a $60m raise at 22c. Web Travel Group’s short interest fell ahead of a guidance beat and up to $90m buyback; shares rose 17.1%.
6 min readSimply Wall St reports Telix Pharmaceuticals (ASX:TLX) said in July 2026 it saw positive Phase 1 ProstACT SELECT data for TLX591-Tx, dosed the first patient in Phase 3 LUTEON for TLX250-Tx, and entered a collaboration with Regeneron. Telix raised FY26 revenue guidance to above US$1B and reported Q2 revenue of US$247M.
4 min readTelix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) will release its financial results for the half-year ended June 30, 2026 on Thursday, August 20, 2026. The Melbourne-based radiopharmaceutical company scheduled the disclosure to provide investors with timely updates on its commercial franchise and late-stage therapeutic pipeline progress during the first half of the year. An investor webcast and conference call will be held immediately following the release at 9:00 a.m.
4 min readThe article says ASX healthcare stocks fell sharply in FY26, with the Health Care sector down 36.1% and CSL, Cochlear, Resmed and Telix each down over 30% to 12 months. It compares Refinitiv consensus EPS forecasts for FY26-28 and UBS EPS estimates, noting earnings are not forecast to collapse as much as share prices. UBS cited sector picks in a 24 July 2026 note.
5 min readAustralia’s S&P/ASX 200 rose 0.72% to 8,886.1 by 1:02 p.m. AEST, up 63.1 points, after a 0.35% gain on Wednesday. The move followed Alphabet’s earnings beat, with revenue up 24% to $119.80B and Google Cloud revenue up 82% to $24.77B. Tech stocks in the index fell, while unemployment stayed at 4.4%.
7 min readTelix Pharmaceuticals shares rose 1.7% to A$15.35 after the company reported June-quarter revenue of $247 million, up 7% QoQ and 21% YoY. Precision Medicine revenue was $202 million, up 30% YoY. Telix expects FY2026 revenue and other income above $1 billion, and updated FY2026 R&D guidance to $230–$270 million, alongside progress in its LUTEON Phase 3 trial.
4 min readTelix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) said the first patient was dosed in its Phase 3 LUTEON trial of TLX250-Tx (177Lu girentuximab tetraxetan) for relapsed or recurrent clear cell renal cell carcinoma. The randomized, open-label, multi-center study evaluates a CAIX-targeted radiopharmaceutical therapy and uses TLX250-Px imaging to select CAIX-positive patients.
3 min readTelix Pharmaceuticals said it completed enrollment of 105 patients in a Phase 3 registration study of TLX591-Px (Illuccix) for prostate cancer imaging in Japan. The data will support a Japan NDA for 68Ga-PSMA-11 PET/CT, and Telix said its Conditional Approval application is under PMDA review.
4 min readTelix Pharmaceuticals opened a radiopharmaceutical research, manufacturing, and treatment facility in Melbourne, Australia, according to the company. The facility is intended to speed delivery of new cancer treatments.
1 min read
